Advertisement

Topics

Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

05:00 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Novel Vaccine to be developed based on Affinivax’s MAPS Vaccine Technology Platform Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worl...

Other Sources for this Article

Affinivax, Inc.
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201
FAX: +81-3-5201-7473
or
For Affinivax, Inc.
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...